PellePharm announced its launch today, with financing from BridgeBio Pharma. The Menlo Park, Calif.-based company is developing a topical gel to treat basal cell carcinoma, including the tumors that result from Gorlin syndrome.
The company’s topical inhibitor compound, patidegib, acts on the hedgehog pathway – a signaling pathway that transmits cellular information for adult tissue maintenance. Abnormal hedgehog signaling has been correlated with a number of cancers including basal cell carcinoma. PellePharm is studying the topical formulation of patidegib in 2 phase II trials. A study evaluating the gel’s use in patients with Gorlin syndrome just completed enrollment, according to the company.
Get the full story at our sister site, Drug Delivery Business News.
The post PellePharm announces launch to develop topical gel for basal cell carcinoma appeared first on MassDevice.
from MassDevice http://ift.tt/2h7xOZK
Cap comentari:
Publica un comentari a l'entrada